RxDoctor Payments Data

Bright Odei, MD

Family Medicine · Harlingen, TXNPI 1023423308

Payments from drug & device makers

$958in general payments, 2019–2025

Across 37 payments — averaging $25.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$137
  • Lilly USA, LLC$124
  • Mauna Kea Technologies, Inc.$118
  • Inspire Medical Systems, Inc.$86
  • AbbVie$83
  • GSK$78
  • plus $332 from 11 others

What the payments were for

  • Food & beverage$958100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$958 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$40,326
Medicare patients
123
Services billed
938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$50,413
FarxigaDapagliflozin Propanediol36$38,529
JardianceEmpagliflozin29$35,222
MounjaroTirzepatide15$27,691
EliquisApixaban20$26,045
JanuviaSitagliptin Phosphate16$24,327
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$13,183
TradjentaLinagliptin14$12,289
Wixela InhubFluticasone Propion/Salmeterol16$4,159
Pravastatin Sodium185$2,763
Atorvastatin Calcium275$2,631
Rosuvastatin Calcium109$2,270
Olmesartan Medoxomil40$1,602
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,540
SynthroidLevothyroxine Sodium24$1,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$31$50,41338 claims
Boehringer IngelheimJardiance, Tradjenta$17$47,51243 claims
AstraZenecaFarxiga$42$38,52936 claims
Lilly USA, LLCMounjaro$124$27,69115 claims
PfizerEliquis$20$26,04520 claims
GSKTrelegy Ellipta$78$13,18315 claims
AbbVieSynthroid$83$1,50524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Harlingen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →